26 April 2023 | Wednesday | News
Cytiva Australia leadership team visit BioCina manufacturing site in Adelaide
Expanded facility to manufacture mRNA-based therapies and vaccines
Researchers at the University of Adelaide will address the design and manufacturing of lipid nanoparticles (LNP) that help deliver mRNA into cells operating companies Precision NanoSystems (PNI) and the life sciences business of Pall are also contributing their technologies to complete the workflow.
This is the company’s first facility in Australia to support GMP manufacturing process from in vitro transcription (IVT) to encapsulated mRNA. Coupled with BioCina’s existing pDNA services, the new mRNA GMP capabilities will establish BioCina as Australia’s first CDMO that can support the manufacturing processes for pDNA, mRNA, encapsulations, and formulations.
Mark W. Womack, CEO, BioCina, says: “We offer comprehensive supply services to biopharmaceutical customers from early-phase clinical trials to commercial production. Cytiva’s ‘from discovery to delivery’ approach perfectly echoes BioCina’s commitment to supporting our customers by providing efficient and cost-effective solutions for developing their programs as they advance towards approval and ultimately to the patients who are waiting.”
Jon Ince, General Manager, Commercial, Australia and New Zealand, Cytiva, says: “While Australia has a highly regarded clinical trials network, and proven track record of R&D collaborations, regional manufacturing capabilities are lagging behind other developed nations, as reported in Cytiva’s 2021 Global Biopharma Resilience Index. At Cytiva we are dedicated to supporting the growth of biotherapeutic manufacturing capabilities through collaborations like these with the University of Adelaide and BioCina. This supports our vision in which access to life-changing therapeutics transforms human health.”
The complete mRNA workflow is supported by the following technologies: